In CVOTs with injectable GLP-1 RAs in people with T2D, the placebo-adjusted blood pressure reductions have been modest, ranging from − 0.7 to − 3.3 mmHg [4, 5, 7, 27, 29]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.